Skip to search formSkip to main contentSkip to account menu

Akt Inhibitor LY2780301

Known as: LY2780301 
An orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer…
1091 Background: Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR)-pathway is frequently activated in… 
2017
2017
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose…
2017
2017
Targeting Aberrant p70S6K Activation for Estrogen Receptor–Negative Breast Cancer Prevention
The prevention of estrogen receptor–negative (ER−) breast cancer remains a major challenge in the cancer prevention field… 
2016
2016
Abstract 2049: Pharmacokinetic drug-drug interaction: a phase Ib dose escalation study of LY2780301 in combination with weekly paclitaxel
Introduction: LY2780301 is an orally available small molecule dual inhibitor of p70 S6 kinase and AKT. LY2780301 is an inhibitor… 
2015
2015
Abstract A56: A dose-escalating phase 1b study assessing the safety, tolerability and efficacy of LY2780301 (a p70S6K/Akt inhibitor) in combination with gemcitabine in molecularly-selected patients…
Background: LY2780301 is an orally available small molecule dual inhibitor of p70S6 kinase and AKT. In non-molecularly selected… 
2012
2012
First-in-human phase I study of LY2780301, an oral P70S6K/AKT inhibitor, in patients with refractory solid tumors.
3005 Background: LY2780301is an oral potent, highly selective ATP competitive inhibitor against p70S6 kinase and AKT. We report… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)